Advances in antiretroviral therapy have increased HIV patient longevity, leading to a rise in cardiovascular complications. Jayadeva Institute has treated over 1,200 such patients.

  • A total of 1,209 HIV-positive patients have received cardiac treatment at Sri Jayadeva Institute since 2013.
  • Improved Antiretroviral Therapy (ART) is extending lives but increasing long-term cardiovascular risks.
  • A multidisciplinary symposium is being organized to integrate HIV and heart care.

The Sri Jayadeva Institute of Cardiovascular Sciences and Research in Bengaluru has reported a significant clinical milestone. Since 2013, the state-run institute has successfully performed cardiac procedures on 1,209 individuals living with HIV (PLHIV). This trend underscores a critical shift in medical priority: the need to integrate cardiovascular monitoring into standard HIV management protocols.

The Evolution of HIV Care

For decades, HIV treatment focused almost exclusively on suppressing viral loads. However, as Dr. H.S. Nataraj Setty, Associate Professor of Cardiology at the institute, points out, the landscape has changed. With the advent of highly effective antiretroviral therapy (ART), HIV is no longer an immediate death sentence but a manageable chronic condition. This increased longevity, while a medical triumph, has brought secondary health concerns to the forefront—most notably, cardiovascular disease.

Read Also:American Visitor Shocked by Inexpensive Home Blood Test Cost in India
HIV care is no longer only about survival; it is about long-term health, dignity, wellness, and quality of life.

Why This Matters

BozokMedia analysis shows that the medical community must transition from a pathogen-centric approach to a holistic patient-centric model. If clinicians only focus on infection control, they risk overlooking treatable heart conditions that can severely impact a patient's long-term prognosis. The intersection of viral management and vascular health is the new frontier in infectious disease care.

The HIV and HEART Symposium 2026

To address these complexities, the Department of Cardiology, in partnership with the AIDS Society of India, is organizing the 'HIV and HEART Symposium 2026'. This high-level gathering will bring together experts in cardiology, microbiology, vascular surgery, and general medicine. The sessions will delve into critical topics such as drug interactions between ART and cardiovascular medications, and the impact of HIV on peripheral arterial disease.

Historical Background

In the early years of the HIV epidemic, mortality was driven by opportunistic infections. As medicine evolved, the focus shifted toward managing the immune system. Today, we face a 'second wave' of health challenges where the aging HIV population faces age-related comorbidities, particularly heart disease, driven by both the virus itself and the metabolic side effects of long-term medication.

Did You Know?: Modern antiretroviral drugs have transformed HIV from a terminal illness into a manageable chronic condition, similar to diabetes.

Frequently Asked Questions

1. Why are HIV patients more prone to heart issues?
Answer: Chronic inflammation caused by the virus and certain long-term antiretroviral medications can contribute to the development of cardiovascular diseases.

2. What is the goal of the upcoming symposium?
Answer: The symposium aims to create an integrated approach to care, ensuring that heart health is treated as a primary component of HIV management.